Study ties survival to inflammatory markers in breast cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Two proteins could become important prognostic markers for long-term survival in breast cancer patients, according to researchers at Seattle’s Fred Hutchinson Cancer Research Center.

Two proteins could become important prognostic markers for long-term survival in breast cancer patients, according to researchers at Seattle’s Fred Hutchinson Cancer Research Center.

The proteins, C-reactive protein (CRP) and serum amyloid A (SAA), are associated with chronic inflammation, known to contribute to cancer development and progression. Cornelia Ulrich, PhD, and colleagues measured the levels of CRP and SAA in 734 breast cancer patients at 31 months after diagnosis. They found elevated levels of CRP and SAA are associated with reduced overall breast cancer survival, regardless of patient age, tumor stage, race, and body mass index (J Clin Oncol online, May 26, 2009).

Women in the highest third of SAA levels were three times more likely to die from breast cancer within seven years than patients in the lowest third. Women in the highest third of CRP levels had a twofold increased risk of death.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.